全文获取类型
收费全文 | 431篇 |
免费 | 14篇 |
国内免费 | 7篇 |
专业分类
儿科学 | 12篇 |
妇产科学 | 6篇 |
基础医学 | 46篇 |
口腔科学 | 5篇 |
临床医学 | 43篇 |
内科学 | 91篇 |
皮肤病学 | 9篇 |
神经病学 | 5篇 |
特种医学 | 155篇 |
外科学 | 22篇 |
综合类 | 3篇 |
预防医学 | 16篇 |
眼科学 | 2篇 |
药学 | 19篇 |
肿瘤学 | 18篇 |
出版年
2022年 | 2篇 |
2021年 | 5篇 |
2020年 | 3篇 |
2019年 | 2篇 |
2018年 | 7篇 |
2016年 | 3篇 |
2015年 | 2篇 |
2014年 | 1篇 |
2013年 | 10篇 |
2012年 | 8篇 |
2011年 | 10篇 |
2010年 | 10篇 |
2009年 | 14篇 |
2008年 | 14篇 |
2007年 | 16篇 |
2006年 | 19篇 |
2005年 | 7篇 |
2004年 | 6篇 |
2003年 | 5篇 |
2002年 | 7篇 |
2001年 | 3篇 |
2000年 | 5篇 |
1999年 | 9篇 |
1998年 | 18篇 |
1997年 | 24篇 |
1996年 | 23篇 |
1995年 | 14篇 |
1994年 | 21篇 |
1993年 | 12篇 |
1992年 | 3篇 |
1991年 | 9篇 |
1990年 | 5篇 |
1989年 | 22篇 |
1988年 | 18篇 |
1987年 | 10篇 |
1986年 | 19篇 |
1985年 | 12篇 |
1984年 | 13篇 |
1983年 | 4篇 |
1982年 | 12篇 |
1981年 | 6篇 |
1980年 | 6篇 |
1979年 | 2篇 |
1978年 | 5篇 |
1977年 | 9篇 |
1976年 | 6篇 |
1975年 | 6篇 |
1971年 | 1篇 |
1961年 | 1篇 |
1935年 | 1篇 |
排序方式: 共有452条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
Life expectancy in British Marfan syndrome populations 总被引:2,自引:0,他引:2
JR Gray AB Bridges RR West L. McLeish AG Stuart JCS Dean MEM Porteous M. Boxer SJ Davies 《Clinical genetics》1998,54(2):124-128
A total of 206 patients with Marfan syndrome were ascertained throughout genetic clinics in Wales and Scotland during the period 1970–1990. There were 45 deaths representing 22% of the cohort. Mean age at death was 45.3 ± 16.5 years. 50% median cumulative survival in the total cohort (n = 206) was 53 years for males and 72 years for females. Multivariate analysis confirmed severity as the best independent indicator of survival. These findings and survival curves will assist in the counselling of British families and individuals with Marfan syndrome. 相似文献
5.
Khalid Ibrahim Bzeizi Richard Smith Ali Albenmousa Madhukar Dama Faisal Aba-Alkhail Rajiv Jalan Dieter Broering 《Transplantation proceedings》2021,53(1):148-158
BackgroundRisk of nephrotoxicity in liver transplant patients on calcineurin inhibitors (CnIs) is a concern. Several controlled trials reported benefit of everolimus (EVR) in minimizing this risk when combined with a reduced CnI dose.BackgroundTo systematically review the efficacy and safety of EVR, alone or with reduced CnI dose, as compared to CnI alone post-liver transplantation.MethodsWe searched MEDLINE, Scopus, and the Cochrane Library for randomized controlled trials comparing EVR- and CnI-based regimens post-liver transplantation. Assessment of studies and data extraction were undertaken independently.ResultsEight studies were selected, describing 769 patients. Cockcroft-Gault GFR was higher at one (P = .05), 3, and 5 years (P = .030) in patients on EVR compared to those receiving CnI therapy. The composite endpoint of efficacy failure was similar between the 2 arms after 1, 3, and 5 years of study. More patients discontinued EVR due to adverse effects in 1 year; however, no difference was noted after 3 or 5 years. A higher rates of proteinuria, peripheral edema, and incisional hernia occurred in patients on EVR.ConclusionsThe analysis confirms noninferiority of EVR and reduced CnI combination. Combination regimen resulted in better renal function compared to standard CnI therapy. 相似文献
6.
7.
Enio R Vasques Estela RR Figueira Joel A Rocha-Filho Cinthia Lanchotte Jorge LS Ximenes Helena B Nader Ivarne LS Tersariol Marcelo A Lima Tiago Rodrigues José EM Cunha Eleazar Chaib Luiz AC D'Albuquerque Flávio HF Galv?o 《Hepatobiliary & pancreatic diseases international : HBPD INT》2022,21(2):190-192
<正>To the Editor:Ischemia-reperfusion injury following surgery and transplantation can lead to irreversible multiorgan failure.Intracellular calcium overload is associated to cellular death during ischemiareperfusion.A recently discovered heparin fragment (HF),trisulfated disaccharide (TD),that acts on sodium-calcium exchanger(NCX) decreasing intracellular Ca2+,showed effectiveness on protecting hepatocytes from ischemia-reperfusion injury [1], 相似文献
8.
Djimdé AA Fofana B Sagara I Sidibe B Toure S Dembele D Dama S Ouologuem D Dicko A Doumbo OK 《The American journal of tropical medicine and hygiene》2008,78(3):455-461
We conducted a randomized single-blinded trial comparing the efficacy and safety of artesunate (AS) + amodiaquine (AQ, 3 days) versus AS (3 days) + sulfadoxine-pyrimethamine (SP, single dose) versus AS monotherapy (5 days) in Southern Mali. Uncomplicated malaria cases were followed for 28 days. Molecular markers of drug resistance were determined. After identification of recrudescences by genotyping, both artemisinin-based combination therapies (ACTs) reached nearly 100% efficacy at Day 14 and Day 28 versus 98.3% and 96.5% for AS, respectively (P > 0.05). AS + SP significantly selected DHFR and DHPS mutations associated with sulfadoxine and pyrimethamine resistance (P < 0.001), and AS + AQ equally selected PfCRT and PfMDR1 point mutations associated with chloroquine and AQ resistance (P < 0.001). No significant adverse event attributable to any of the study drugs was found. The ACTs were efficacious and safe, but the selection of markers for resistance to the partner drugs raises concerns over their lifespan in areas of intense malaria transmission. 相似文献
9.
Extracellular matrix of cultured bovine aortic endothelial cells contains functionally active type 1 plasminogen activator inhibitor 总被引:17,自引:0,他引:17
The extracellular matrix (ECM) of cultured bovine aortic endothelial cells (BAEs) was analyzed by immunoblotting and reverse fibrin autography and shown to contain type 1 plasminogen activator inhibitor (PAI-1). Most PAI-1 in the ECM formed complexes with exogenously added tissue-type plasminogen activator (tPA), demonstrating that this PAI-1 was functionally active. The resulting tPA/PAI-1 complexes were recovered in the reaction solution, indicating that the PAI-1 in such complexes no longer bound to ECM. The PAI-1 could not be removed by incubating ECM in high salt (2 mol/L NaCl), sugars (1 mol/L galactose, 1 mol/L mannose), glycosaminoglycans (10 mmol/L heparin, 10 mmol/L dermatan sulfate), or epsilon-aminocaproic acid (0.1 mol/L). However, PAI-1 could be extracted from ECM by treatment with either arginine (0.5 mol/L) or potassium thiocyanate (2 mol/L), or by incubation under acidic conditions (pH 2.5). ECM depleted of PAI-1 by acid extraction was able to bind both the active and latent forms of PAI-1. In this instance, most of the bound PAI-1 did not form complexes with tPA, indicating that the latent form was not activated as a consequence of binding to ECM. Although the PAI-1 activity in conditioned medium decayed with a half-life (t 1/2) of less than 3 hours, the t 1/2 of ECM- associated PAI-1 was greater than 24 hours. These data suggest that PAI- 1 is produced by cultured BAEs in an active form and is then either released into the medium where it is rapidly inactivated or into the subendothelium where it binds to ECM. The specific binding of PAI-1 to ECM protects it from this inactivation. 相似文献
10.
M. MICHAELA OTT ANITA HELBING GERMAN OTT JIRI BARTEK LARS FISCHER ALEXANDER DÜRR HANS KREIPE HANS K. MÜLLER-HERMELINK 《The Journal of pathology》1996,179(3):238-242
Centrocytic lymphoma, or mantle cell lymphoma (MCL), is characterized by a chromosomal translocation t(11;14) (q13;q32) involving the bcl-1 locus on chromosome 11. Cyclin D1 is a cell-cycle regulatory protein essential for G1–S transition and has been identified as a potential transforming gene affected by the translocation. In this study, 32 cases of MCL were analysed for the bcl-1 rearrangement and cyclin D1 protein expression. In 17 cases, a rearrangement at the major translocation cluster of bcl-1 could be detected. Twenty-four cases exhibited nuclear cyclin D1 expression that was not detectable in other B-cell lymphomas ( n =40) or in normal B-cells. In nine MCL samples, cyclin D1 was expressed without a detectable bcl-1 rearrangement. The detection of a t(11;14) by means of classical cytogenetics in one of these cases, however, may suggest that this discrepancy could be due to chromosomal breakages outside the typical translocation cluster region. In two cases, a bcl-1 rearrangement was not accompanied by cyclin D1 expression. This study provides further evidence that cyclin D1 is involved in the pathogenesis of MCL and can be exploited as a diagnostic marker in the differential diagnosis of B-cell lymphomas and in the identification of MCL. 相似文献